Product Theaters 2014

Product Theaters provide an opportunity for a commercial organization (Exhibitor) to present information about its products or services or new research findings to ICAAC 2014 attendees. The Product Theater space is located in the Exhibit Hall. Material presented in Product Theaters may be promotional and may concentrate on a specific product. Therefore, these demonstrations are considered promotional and do not offer continuing education credits.

 

 


 

Sunday, September 7

LifeScale: High-Resolution Growth Analysis and (Truly) Rapid AST’s by Microbe Mass Measurement
Supported by Affinity Biosensors

Affinity-Biosensors-Logos

11:30 a.m.–12:15 p.m.
Exhibit Hall
Product Theater Booth #218

Speakers:

Ken Babcock, PhD
CEO, Affinity Biosensors

Cynthia Schneider, PhD
Senior Scientist, Affinity Biosensors

Program Overview:
A new method for measuring cell mass and growth is revolutionizing cytometry.  This presentation will introduce the LifeScale platform, melding high-throughput measurement of thousands of cells with precision measurement of individual microbe mass.  LifeScale is being developed in two formats:  

LifeScale: a flexible, multi-sample, benchtop format for custom mixtures of media and microbes. Combining counting, individual microbe mass, and high-resolution optical microscopy, LifeScale provides a data set unequaled for drug discovery, emerging resistance profiles, quality control, and microbiome research applications.

LifeScale AST:  provides a well-plate format for rapid (2 hour) AST's.  Adding automation, high throughput, and excellent statistics to the LifeScale system gives the fastest possible assessment of microbial growth.  AST performance has been validated on clinical blood direct from culture, and both raw and plated urine samples. LifeScale AST uses standard reference-method preparation for compatibility with existing work flow, and is an ideal companion for molecular or MALDI identification methods.

 

Pneumococcal Disease in Adults: Key Considerations for Your Office, Hospital, or Pharmacy
Supported by Merck

Merck 2C

12:30 p.m.–1:15 p.m.
Exhibit Hall
Product Theater Booth #218

Speaker:

Paul S. Schulz, MD
System Epidemiologists and Medical Director, Infection Prevention and Employee Health at Norton Healthcare Board certified in the areas of Internal Medicine and Infectious Disease

 

Learning Objectives:
- Describe pneumococcal disease burden
- Understand the clinical significance of pneumococcal serotypes
- Discuss pneumococcal disease in adult patients

 

 

Monday, September 8

One 22-Minute Multiplex Assay for the Detection of 9 Targets Including ampCs, ESBLs, MBLs, and KPCs Using Rapid PCR Amplification
Supported by Streck

StreckLOGOprintEPS

11:30 a.m.–12:15 p.m.
Exhibit Hall
Product Theater Booth #218

Speaker:

Nancy D. Hanson, PhD
Creighton University

Program Overview
: 
Gram-negative organisms resistant to β-lactams often produce multiple β-lactamases, making phenotypic detection of medically important β-lactamases difficult. Identification of these resistance mechanisms is key in controlling the spread of infection, and can help determine the best therapeutic options for patients. Molecular diagnostics can aid in detecting resistance mechanisms, however, PCR amplification using conventional or Real-Time PCR cyclers can take 2-3 hours to complete. This presentation describes a multiplex assay that detects 8 important β-lactamase gene families (blaCMY-2, blaDHA, blaVIM, blaNDM, blaKPC, blaIMP-1, blaCTX-M-14, and blaCTX-M-15) and an internal control gene within one reaction using rapid PCR amplification technology. The development of this assay included the use of the Q5® DNA polymerase, one primer mix vial, two internal control vials, and the Philisa® Thermal Cycler. Clinical isolates evaluated included E. coli, Klebsiella spp, Enterobacter spp., and Pseudomonas spp. Previously validated test isolates using singleplex PCR were positive for multiple β-lactamases including 2 NDM producing isolates that also carried blaCMY-2-like and blaCTX-M-15-like and the ATCC strain BAA-2452 that carried blaCMY-2-like in addition to the advertised blaNDM. This multi-gene multiplex assay is a rapid (22-min) molecular diagnostic tool for detection of multiple beta-lactamase gene families of medical importance.